Stocks
Verastem, Inc.VSTM
NASDAQHealthcareBiotechnology$10.04
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted therapies for RAS-driven cancers, including lung and pancreatic tumors. Its lead programs focus on the dual inhibition of MEK and the NF-kB pathway, with ongoing trials in KRAS-mutant solid tumors. Investors track Verastem for its potential to address difficult-to-treat cancer subtypes and its progress through late-stage clinical development.
52W Range: $3.43-$10.82
Congressional Interest in Verastem, Inc. (VSTM)
No congressional trades have been disclosed for Verastem, Inc. (VSTM) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading VSTM?
No congressional trades found for this stock.